Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 1/2019

01-01-2019 | Correction

Correction to: Aromatase inhibitor-induced carpal tunnel syndrome: prevalence in daily practice

Authors: Soumaya Labidi, Nesrine Mejri, Houda El Benna, Mehdi Afrit, Sarra Lakhdher, Hamouda Boussen

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2019

Login to get access

Excerpt

The original version of this article unfortunately contained a mistake. The given name and family name were swapped. …
Metadata
Title
Correction to: Aromatase inhibitor-induced carpal tunnel syndrome: prevalence in daily practice
Authors
Soumaya Labidi
Nesrine Mejri
Houda El Benna
Mehdi Afrit
Sarra Lakhdher
Hamouda Boussen
Publication date
01-01-2019
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2019
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-018-3745-y

Other articles of this Issue 1/2019

Cancer Chemotherapy and Pharmacology 1/2019 Go to the issue

Original Article

Steroidal dimer by001 inhibits proliferation and migration of esophageal cancer cells via multiple mechanisms

Original Article

Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA)

Original Article

Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis

Original Article

Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms

Review Article

Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters

Original Article

Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits